We are live on ! Find out more
CELG.RT

Bristol-Myers Squibb Rights

21 hedge funds and large institutions have $164K invested in Bristol-Myers Squibb Rights in 2021 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% less ownership

Funds ownership: 0.03%0.03% (-0%)

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

5% less funds holding

Funds holding: 2221 (-1)

46% less capital invested

Capital invested by funds: $303K → $164K (-$139K)

75% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 4

Holders
21
Holders Change
-1
Holders Change %
-4.55%
% of All Funds
0.32%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
3
Increased
1
Reduced
4
Closed
3
Calls
Puts
Net Calls
Net Calls Change

CELG.RT Hedge Fund Activity: Q4 2021 in Review

21 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb Rights (CELG.RT) for Q4 2021, worth a combined $164K — down 46% from $303K a quarter earlier.

Fund positioning in CELG.RT was balanced in Q4 2021: 3 funds opened new positions, 3 closed out, 1 added to existing stakes and 4 trimmed.

The largest buyer was Maven Securities, opening a new position worth an estimated $12.7K. The largest seller was Boothbay Fund Management, exiting entirely with an estimated $177K sold.

  • 21 institutional investors held Bristol-Myers Squibb Rights (CELG.RT) as of Q4 2021, down from 22 in Q3 2021.
  • Funds reported $164K of Bristol-Myers Squibb Rights stock for Q4 2021, down 46% quarter-over-quarter.
  • 3 funds opened new Bristol-Myers Squibb Rights positions in Q4 2021 and 3 closed out, a net change of 0 holders.
  • The largest Bristol-Myers Squibb Rights buyer in Q4 2021 was Maven Securities, an estimated $12.7K added.
  • The largest Bristol-Myers Squibb Rights seller in Q4 2021 was Boothbay Fund Management, an estimated $177K sold.

Based on aggregated 13F filings for Q4 2021.